Table 2.
HRs (95% CI) for the effect of early treatment with losartan on long-term outcomes in each baseline albuminuria stratum and for the combined strata
| Outcome | Baseline stratum |
||||
|---|---|---|---|---|---|
| N events | Normoalbuminuria | Microalbuminuria | P value for interaction | Combined | |
| Primary GFR outcome* | 52 | 1.04 (0.48–2.25) | 0.56 (0.29–1.07) | 0.20 | 0.72 (0.44–1.18) |
| Elevated albuminuria (ACR ≥30 mg/g) | 75 | 1.02 (0.65–1.62) | — | — | — |
| Macroalbuminuria | 86 | 1.40 (0.71–2.78) | 0.68 (0.40–1.18) | 0.11 | 0.90 (0.59–1.39) |
| Death | 58 | 1.07 (0.53–2.17) | 0.54 (0.25–1.18) | 0.22 | 0.79 (0.47–1.32) |
| End-stage renal disease or death | 73 | 1.32 (0.70–2.51) | 0.57 (0.29–1.11) | 0.08 | 0.88 (0.56–1.40) |
*Decline in GFR to ≤60 mL/min or to half of the baseline value in persons who entered with GFR <120 mL/min.